Business
Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care
STOUGHTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have two poster presentations
About this update from Collegium Pharmaceutical, Inc.
[{"type":"text","content":"STOUGHTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have two poster presentations highlighting real-world data from its differentiated neuropsychiatry product, Jornay PM, (methylphenidate HCl), a central nervous system (CNS) stimulant for the treatment of attention deficit hyperactivity disorder (ADHD) at the National Association of Pediatric Nurse Practitioners (NAPNAP) 46th National Conference on Pediatric Health Care, being held in Chicago, IL, from March 10-13, 2025. “Collegium is pleased to present real-world data at NAPNAP as part of our commitment to providing differentiated medicines that help to improve the lives of people living with serious medical conditions. The data being presented demonstrates the real-world benefit of Jornay PM as an important therapeutic option for the ADHD community,” said Thomas Smith, M.D., Chief Medical Officer of Collegium. The following posters will be available and on display to attendees in Riverside Center Exhibit Hall in the East Tower during exhibit hall hours:Monday, March 10: 12:00 pm - 1:30 pm, 6:00 pm - 7:30 pm CTTuesday, March 11: 8:00 am - 10:00 am, 12:15 pm - 2:15 pm CT Poster Title:#9: Real-World Persistence and Adherence with Delayed-Release/Extended-Release Methylphenidate from a Large US Claims Database AnalysisAuthors:Vamshi Ruthwik Anupindi, MS; Swapna Munnangi, PhD; Mitchell DeKoven, MHSA; Michelle D. Po, PhD; Cassandra L. Uchida, PhD; Lewis E. Warrington, MD Poster Title:#10: Real-World Utilization of Delayed-Release/Extended-Release Methylphenidate: Demographic and Dosing Data from a Large US Claims Database AnalysisAuthors:Vamshi Ruthwik Anupindi, MS; Swapna Munnangi, PhD; Mitchell DeKoven, MHSA; Michelle D. Po, PhD; Cassandra L. Uchida, PhD; Lewis E. Warrington, MD About ADHD ADHD is among the most common childhood psychiatric conditions with behavioral symptoms fluctuating throughout the day. It is usually first diagnosed in childhood and often lasts into adulthood. Children with ADHD may have trouble paying attention, controlling impulsive behaviors, or be overly active. Many home-based difficulties for children and adolescents with ADHD occur during the early morning routine (e.g., before the school day begins). About JORNAY PM®JORNAY PM (methylphenidate HCl extended-release capsules) is a cent...